The American Cancer Society estimates that over 80,000 individuals will be diagnosed with bladder cancer this year.
Stocktwits on MSN
IBRX stock finds retail cheer after company’s immunotherapy for bladder cancer gets Saudi FDA approval
ImmunityBio plans to establish a regional office in Saudi Arabia to support its expansion across the Middle East and North ...
Overall survival appears no worse for patients with organ-confined limited-stage small cell bladder cancer receiving multimodal organ-preserving treatment. For patients with limited-stage small-cell ...
InvestorsHub on MSN
Theralase and Ferring ink deal for new bladder cancer study
Theralase Technologies (USOTC:TLTFF) signed a clinical development agreement with Ferring Pharmaceuticals, a top name in ...
Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis.
Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.
Armistice Capital acquired more shares of ImmunityBio as EMA recommended ANKTIVA approval and Q3 2025 product revenue surged ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback